What Sempresto does

Sempresto, Inc. is a US-based, pre-revenue medical device company founded in 2024 and headquartered in Weston (also referenced as Boston) that is developing a platform of smartphone-integrated rescue drug delivery devices. The company targets patients at risk of acute medical emergencies—severe allergies and anaphylaxis, epilepsy and seizures, severe hypoglycemia in diabetics, and opioid overdose—who require immediate access to rescue medication. Its flagship product is an ultra-portable epinephrine autoinjector with a 3/8 inch profile that attaches directly to any smartphone case, designed to address the documented gap that 60% of patients do not have epinephrine accessible during an anaphylactic emergency and 41% say they would carry an autoinjector more often if it were more convenient. The hardware is paired with a companion mobile application that delivers training, refill reminders, and emergency contact support.

The underlying technology originated at Thomas Jefferson University under Dr. Edmund Pribitkin, and Sempresto holds an exclusive worldwide license to commercialize it. The company has rapidly consolidated IP by acquiring the Alerje mobile device-integrated auto-injector platform (December 2025) and the Steven A. Friedman patent portfolio covering novel mechanisms and safety features (November 2025). It has also formed a strategic partnership with Health Alliance Global (Heal All) to integrate the device with 24/7 virtual care and emergency telehealth, and a broad research partnership with Thomas Jefferson University.

The business model is direct-to-consumer hardware sales to individual patients, with stated future potential for distribution through healthcare providers and pharmacies. Pricing has not been publicly disclosed. The company is pre-revenue, operates with 1-10 employees, and is currently raising a community investment round. The leadership team comprises CEO and co-founder Elizabeth Reczek, PhD; Executive Chairman and co-founder Shawn Marcell; co-founder and Scientific Advisory Board Chair Edmund Pribitkin, MD, MBA, FACS; CFO Matthew Copeland, MBA; and CTO Gregory Dale. Regulatory milestones for commercialization are not yet disclosed in available materials.

Name

Sempresto

Legal name

Sempresto, Inc.

Website

https://sempresto.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Sempresto is a pre-revenue US medical device company developing ultra-portable, smartphone-attached autoinjectors for rescue drugs including epinephrine, midazolam, glucagon, and naloxone, serving patients at risk of anaphylaxis, seizures, hypoglycemia, and opioid overdose.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Wearable Injectors & On-Body Delivery Systems (HLAHAIAE)

akta.pro secondary industry

Glucagon Rescue Delivery Devices (Auto-Injectors, Nasal) (HLAHAHAK)

Keywords

• Smartphone medical devices
• Rescue drug delivery
• Epinephrine autoinjectors
• Connected medical devices
• Emergency medication delivery

Headquarters

HQ city

Weston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

1. Hardware Device Sales: Sale of smartphone-integrated autoinjector devices for epinephrine and other rescue medications. The company is developing products for anaphylaxis, seizures, hypoglycemia, and opioid overdose, generating revenue through device sales to patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sempresto develops and is commercializing ultra-portable, smartphone-integrated medical devices (autoinjectors) for rescue drug delivery. The flagship product is an epinephrine autoinjector designed to attach seamlessly to any phone case with a 3/8 inch profile, paired with a companion mobile app providing training, refill reminders, and emergency contact support. The company is also building additional rescue medication platforms for seizures (midazolam), hypoglycemia (glucagon), and opioid overdose (naloxone).

Product overview

Sempresto is developing a platform of smartphone-integrated rescue drug delivery devices with its flagship product being a smartphone-integrated epinephrine autoinjector that attaches seamlessly to any phone case. The company has acquired three autoinjector platforms (Alerje, Steven A. Friedman, and a third unnamed platform) to build a comprehensive IP portfolio. The product ecosystem includes multiple rescue medication platforms targeting anaphylaxis (epinephrine), seizures (midazolam), hypoglycemia (glucagon), and opioid overdose (naloxone), all designed with a compact 3/8 inch profile for portability. A companion mobile app provides training resources, refill reminders, and emergency contact support. The company is also developing partnerships for smart communication platforms integrating patientside diagnostics and virtual care with rescue medication delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• Smartphone-Integrated Epinephrine Autoinjector Ultra-portable epinephrine autoinjector (3/8 inch profile) that attaches seamlessly to any smartphone case, providing always-available emergency medication for severe allergy sufferers; features an easy unlock safety mechanism and integrates with a companion mobile app for training, refill reminders, and emergency contact support.
• Companion Mobile App Mobile application paired with the smartphone-integrated autoinjector that delivers training resources, refill reminders, emergency contact support, and integration with virtual care services to drive better patient outcomes.
• Seizure Rescue Medication Platform Smartphone-integrated autoinjector platform delivering midazolam for immediate seizure abort and prevention of prolonged status epilepticus, designed for the approximately 50 million people worldwide affected by epilepsy.
• Hypoglycemia Rescue Medication Platform Smartphone-integrated autoinjector platform delivering glucagon for severe hypoglycemia in diabetic patients, addressing the nearly 300,000 US emergency room visits per year from low blood sugar emergencies.
• Opioid Overdose Rescue Medication Platform Ultra-portable smartphone-integrated naloxone autoinjector device intended to increase availability of the antidote and save lives from preventable overdoses, addressing the over 100,000 deaths per year in the US from opioid overdoses.

Quantifiable outcome

• Addresses the 60% of patients who don't have epinephrine accessible during an anaphylactic emergency
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Thomas Jefferson UniversitycoreStrategic or Co-development Partner · 10 December 2025Broad strategic partnership expanding upon the existing exclusive license, aimed at advancing Sempresto's smartphone-integrated rescue medication platform. The partnership accelerates innovation and ensures platform alignment with real-world needs of patients, physicians, and payors.
• Health Alliance Global (Heal All)coreStrategic or Co-development Partner · 6 November 2025Strategic collaboration to develop a smart communication platform integrating patientside diagnostics and virtual care with rescue medication delivery. The jointly-developed application will automatically connect patients using Sempresto's device directly with Heal All's team of emergency-trained nurses, nurse practitioners, and physicians, providing expert medical guidance at the moment of need.
• Thomas Jefferson UniversitycoreOEM/ Whitelabel/ Licensing Partner · 4 November 2025Exclusive, worldwide licensing agreement for the innovative smartphone-integrated epinephrine autoinjector technology invented by Dr. Edmund Pribitkin, Chief Physician Executive and EVP at Jefferson Health. Dr. Pribitkin serves as Chair of Sempresto's Scientific Advisory Board. The agreement provides Sempresto rights to commercialize the breakthrough device.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Pfizer: Pfizer (through legacy Hospira) has historically competed in generic epinephrine injectors and operates broadly in injectable drug delivery. It is a broad incumbent that could either acquire competing technology or use scale advantages to pressure Sempresto's pricing and distribution.
• Insulet: Insulet's Omnipod is the leading wearable, on-body drug delivery platform for insulin. While not a direct competitor in rescue drugs, it represents the broader wearable/connected drug-delivery category and a relevant benchmark for connected injection devices and regulatory pathway.
• Viatris: Viatris (via legacy Mylan) markets EpiPen, the dominant epinephrine autoinjector franchise with deep prescriber relationships and pharmacy distribution. It is the market-share incumbent Sempresto must displace in the anchor anaphylaxis indication.
• Emergent BioSolutions: Emergent BioSolutions, through its acquisition of Adamis Pharmaceuticals, markets Symjepi, a prefilled epinephrine syringe/injector. It competes directly in the rescue-epinephrine category and adds scale, manufacturing infrastructure, and government contracts that Sempresto lacks.

Emerging players

• Crossject: Crossject develops needle-free, pre-filled, single-use rescue injectors including for epilepsy and emergency indications. It overlaps with Sempresto's planned midazolam seizure rescue and broader rescue-injection platform thesis, representing a non-smartphone-attached but form-factor-innovative alternative.
• Xeris Biopharma: Xeris Biopharma markets Gvoke (glucagon) and other ready-to-use rescue formulations, directly competing with Sempresto's planned glucagon hypoglycemia rescue platform. It is an emerging player with approved products and is most relevant to Sempresto's hypoglycemia indication.
• ARS Pharmaceuticals: ARS Pharma developed and recently launched Neffy, the first needle-free nasal epinephrine spray for anaphylaxis. It targets the exact same patient population as Sempresto with an alternative administration route, raising the bar for any convenience advantage claimed by a smartphone-mounted autoinjector.

Direct peers

• Kaleo: Kaleo manufactures Auvi-Q, the most prominent branded competitor to EpiPen in the epinephrine autoinjector market. It is the closest direct competitor to Sempresto in target patients (severe allergy), product format (compact autoinjector with voice/visual prompts), and DTC-adjacent go-to-market.
• Amneal Pharmaceuticals: Amneal manufactures and distributes a generic epinephrine autoinjector. It is a direct competitor to Sempresto in the same rescue-drug category and brings established generic commercial infrastructure and payer contracts.
• Teva Pharmaceutical Industries: Teva supplies a generic epinephrine autoinjector that competes on price in the same patient population. As a generic incumbent, it pressures Sempresto's pricing flexibility and could limit payer uptake of a premium-priced smartphone-integrated device.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sempresto

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sempresto